|
1）Zoutendijk R, Reijnders JG, Zoulim F, et al. Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis. Gut. 2013; 62: 760-5
|
|
|
|
2）Kim SS, Hwang JC, Lim SG, et al. Effect of virological response to entecavir on the development of hepatocellular carcinoma in hepatitis B viral cirrhotic patients: comparison between compensated and decompensated cirrhosis. Am J Gastroenterol. 2014; 109: 1223-33
|
|
|
|
|
|
3）Nishikawa H, Osaki Y. Clinical significance of therapy using branched-chain amino acid granules in patients with liver cirrhosis and hepatocellular carcinoma. Hepatol Res. 2014; 44: 149-58
|
|
|
|
|
4）Toshikuni N, Arisawa T, Tsutsumi M. Nutrition and exercise in the management of liver cirrhosis. World J Gastroenterol. 2014; 20: 7286-97
|
|
|
|
|
|
5）Kawaguchi T, Shiraishi K, Ito T, et al. Branched-chain amino acids prevent hepatocarcinogenesis and prolong survival of patients with cirrhosis. Clin Gastroenterol Hepatol. 2014; 12: 1012-8. e1
|
|
|
|
|
|
6）Sakai Y, Iwata Y, Enomoto H, et al. Two randomized controlled studies comparing the nutritional benefits of branched-chain amino acid (BCAA) granules and a BCAA-enriched nutrient mixture for patients with esophageal varices after endoscopic treatment. J Gastroenterol. 2014 Mar 17. [Epub ahead of print]
|
|
|
|
|
|
7）Iwasa M, Kobayashi Y, Mifuji-Moroka R, et al. Branched-chain amino acid supplementation reduces oxidative stress and prolongs survival in rats with advanced liver cirrhosis. PloS One. 2013; 8: e70309
|
|
|
|
|
|
8）Jiang Q, Jiang G, Shi KQ, et al. Oral acetyl-L-carnitine treatment in hepatic encephalopathy: view of evidence-based medicine. Ann Hepatol. 2013; 12: 803-9
|
|
|
|
|
|
9）Ishikawa H, Takaki A, Tsuzaki R, et al. L-carnitine prevents progression of non-alcoholic steatohepatitis in a mouse model with upregulation of mitochondrial pathway. PloS One. 2014; 9: e100627
|
|
|
|
|
|
10）Sakaida I, Yamashita S, Kobayashi T, et al. Efficacy and safety of a 14-day administration of tolvaptan in the treatment of patients with ascites in hepatic oedema. J Int Med Res. 2013; 41: 835-47
|
|
|
|
|
|
11）Sakaida I, Kawazoe S, Kajimura K, et al. Tolvaptan for improvement of hepatic edema: A phase 3, multicenter, randomized, double-blind, placebo-controlled trial. Hepatol Res. 2014; 44: 73-82
|
|
|
|
|
|
12）Egawa H, Nishimura K, Teramukai S, et al. Risk factors for alcohol relapse after liver transplantation for alcoholic cirrhosis in Japan. Liver Transpl. 2014; 20: 298-310
|
|
|
|
|
|
13）Egawa H, Ueda Y, Kawagishi N, et al. Significance of pretransplant abstinence on harmful alcohol relapse after liver transplantation for alcoholic cirrhosis in Japan. Hepatol Res. 2014 Apr 2. [Epub ahead of print]
|
|
|
|
|
|
14）Terai S, Takami T, Yamamoto N, et al. Status and prospects of liver cirrhosis treatment by using bone marrow-derived cells and mesenchymal cells. Tissue Eng Part B Rev. 2014; 20: 206-10
|
|
|
|
|
|
15）寺井 崇，坂井田功．【肝臓の発生・再生】 自己骨髄細胞投与による肝再生，修復治療．生化学．2012; 84: 707-11
|
|
|
|
|
|
16）Terai S, Ishikawa T, Omori K, et al. Improved liver function in patients with liver cirrhosis after autologous bone marrow cell infusion therapy. Stem Cells. 2006; 24: 2292-8
|
|
|
|
|
|
17）Kim JK, Park YN, Kim JS, et al. Autologous bone marrow infusion activates the progenitor cell compartment in patients with advanced liver cirrhosis. Cell Transplant. 2010; 19: 1237-46
|
|
|
|
|
|
18）Saito T, Okumoto K, Haga H, et al. Potential therapeutic application of intravenous autologous bone marrow infusion in patients with alcoholic liver cirrhosis. Stem Cells Dev. 2011; 20: 1503-10
|
|
|
|
|
|
19）Tanimoto H, Terai S, Taro T, et al. Improvement of liver fibrosis by infusion of cultured cells derived from human bone marrow. Cell Tissue Res. 2013; 354: 717-28
|
|
|
|
|
|
20）Bayart E, Cohen-Haguenauer O. Technological overview of iPS induction from human adult somatic cells. Curr Gene Ther. 2013; 13: 73-92
|
|
|
|
|
|
21）Chen YF, Tseng CY, Wang HW, et al. Rapid generation of mature hepatocyte-like cells from human induced pluripotent stem cells by an efficient three-step protocol. Hepatology. 2012; 55: 1193-203
|
|
|
|
|
|
22）Inamura M, Kawabata K, Takayama K, et al. Efficient generation of hepatoblasts from human ES cells and iPS cells by transient overexpression of homeobox gene HEX. Mol Ther. 2011; 19: 400-7
|
|
|
|
|
|
23）Watanabe H, Takayama K, Inamura M, et al. HHEX promotes hepatic-lineage specification through the negative regulation of eomesodermin. PloS One. 2014; 9: e90791
|
|
|
|
|
|
24）Lee MO, Moon SH, Jeong HC, et al. Inhibition of pluripotent stem cell-derived teratoma formation by small molecules. Proc Nat Acad Sci U S A. 2013; 110: E3281-90
|
|
|
|
|
|
25）Tan CY, Lai RC, Wong W, et al. Mesenchymal stem cell-derived exosomes promote hepatic regeneration in drug-induced liver injury models. Stem Cell Res Ther. 2014; 5: 76
|
|
|
|
|
|
26）Xagorari A, Siotou E, Yiangou M, et al. Protective effect of mesenchymal stem cell-conditioned medium on hepatic cell apoptosis after acute liver injury. Int J Clin Exp Pathol. 2013; 6: 831-40
|
|
|
|
|
|
27）Mederacke I, Hsu CC, Troeger JS, et al. Fate tracing reveals hepatic stellate cells as dominant contributors to liver fibrosis independent of its aetiology. Nat Commun. 2013; 4: 2823
|
|
|
|
|
|
28）Iwaisako K, Brenner DA, Kisseleva T. Whatʼs new in liver fibrosis? The origin of myofibroblasts in liver fibrosis. J Gastroenterol Hepatol. 2012; 27 Suppl 2: 65-8
|
|
|
|
|
|
29）Seki E, Schwabe RF. Hepatic Inflammation and Fibrosis: Functional Links and Key Pathways. Hepatology. 2014 Jul 26. [Epub ahead of print]
|
|
|
|
|
|
30）Pradere JP, Kluwe J, De Minicis S, et al. Hepatic macrophages but not dendritic cells contribute to liver fibrosis by promoting the survival of activated hepatic stellate cells in mice. Hepatology. 2013; 58: 1461-73
|
|
|
|
|
|
31）Marra F, Tacke F. Roles for Chemokines in Liver Disease. Gastroenterology. 2014; 147: 577-94. e71
|
|
|
|
|
|
32）Pellicoro A, Ramachandran P, Iredale JP, et al. Liver fibrosis and repair: immune regulation of wound healing in a solid organ. Nat Rev Immunol. 2014; 14: 181-94
|
|
|
|
|
|
33）Yoshiji H, Noguchi R, Namisaki T, et al. Combination of sorafenib and angiotensin-II receptor blocker attenuates preneoplastic lesion development in a non-diabetic rat model of steatohepatitis. J Gastroenterol. 2013 Nov 7. [Epub ahead of print]
|
|
|
|
|
|
34）Seki E, Brenner DA, Karin M. A liver full of JNK: signaling in regulation of cell function and disease pathogenesis, and clinical approaches. Gastroenterology. 2012; 143: 307-20
|
|
|
|
|
|
35）Yoshiji H, Noguchi R, Ikenaka Y, et al. Combination of branched-chain amino acid and angiotensin-converting enzyme inhibitor improves liver fibrosis progression in patients with cirrhosis. Mol Med Rep. 2012; 5: 539-44
|
|
|
|
|